Treatment of Peyronie's disease with oral colchicine: long‐term results and predictive parameters of successful outcome

Kadıoğlu, Ateş; Tefekli̇, Ahmet; Koksal, Turker; Usta, Murat; Erol, Hasan Fehmi

doi:10.1038/sj.ijir.3900519

Cited by 98 publications

(50 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This low prevalence of side effects among young men in this study is compatible with long-term results of our own previously published series, in which only 1.7% terminated colchicine treatment due to severe side effects. 25 Surgical treatment can also be considered among patients with Peyronie's disease presenting under age 40 y when the acute phase resolves. 3,13,14,18 According to the algorithm, generally accepted as a consensus by several authors, reconstructive surgery should be preferred for these young patients since they are all potent or have a positive response to CIS test.…”

Section: Discussionmentioning

confidence: 99%

“…23 ± 25 Initial doses ranged from 0.5 to 1.0 mg daily during the ®rst week and were increased gradually until the maximum dose of 2.0 mg daily was reached. 25 Three to 6 months of treatment was recommended. 25 Complete blood count was obtained prior to therapy and every 2 months during therapy.…”

Section: Treatment Strategymentioning

confidence: 99%

“…25 Three to 6 months of treatment was recommended. 25 Complete blood count was obtained prior to therapy and every 2 months during therapy. The success of the treatment was based on the criteria such as decrease in pain on erection and decrease of the degree of penile curvature, while improvement of the curvature was de®ned as straightening of the penis or signi®cant decrease in the penile curvature, permitting sexual intercourse possible, if previously not.…”

Section: Treatment Strategymentioning

confidence: 99%

See 2 more Smart Citations

Peyronie's disease in men under age 40: characteristics and outcome

et al. 2001

Self Cite

View full text Add to dashboard Cite

Peyronie's disease is most commonly seen in the ®fth decade of life. However, a wide range of age (20 ± 83 y) is reported. During a 6-year period, men with Peyronie's disease presenting under the age of 40 were reviewed retrospectively and followed-up. The prevalence of Peyronie's patients presenting under age 40 was 8.2%. Their mean age was 32.47 AE 5.37 (range: 23 ± 39) y and 78.9% of them presented during the acute phase of the disease. Pain on erection was a part of presenting symptom complex in 52.6% and the majority (84%) had a degree of penile curvature`60 . Erectile dysfunction (ED) was present in 21% of patients, who responded well to intracavernous injection test. After a minimal 2-year follow-up, improvement in penile deformity was observed in 36.8%, and 42.1% had stable disease while 21% experienced deterioration of the penile curvature. The onset of Peyronie's disease is clinically more noisy and acute in patients presenting under age 40 and this forces the physicians to treat them more vigorously.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Treatment Strategymentioning

confidence: 99%

Section: Treatment Strategymentioning

confidence: 99%

See 1 more Smart Citation

Peyronie's disease in men under age 40: characteristics and outcome

et al. 2001

Self Cite

View full text Add to dashboard Cite

show abstract

“…The primary reported side effect of colchicine is gastrointestinal upset with diarrhea. A subsequent noncontrolled study of colchicine response was performed in a group of patients with acute Peyronie's disease by Kadioglu et al 18 They examined the results of 1 mg of colchicine twice per day for 2-6 months with a mean follow-up of 11 months. The pain was diminished in 95%, curvature was measured and noted to be diminished in 30%, but worse in 21.7% of subjects.…”

Section: Oral Therapymentioning

confidence: 99%

Review of current nonsurgical management of Peyronie's disease

Levine

2003

Int J Impot Res

View full text Add to dashboard Cite

The current nonsurgical treatment options for men with Peyronie's disease is reviewed. The treatments currently employed and published in the English literature are discussed. A wide variety of nonsurgical treatment options are available to the practicing physician, including oral and topical medications, intralesional injection therapy, as well as employing external energy sources to drive medicine into the tunica albuginea by iontophoresis or direct stimulation of plaque change by shock wave therapy. Nonsurgical treatment of Peyronie's disease clearly has a place in the armamentarium of the practicing urologist. Oral therapy appears to have little therapeutic benefit. Injection and topical approaches deserve further attention. Yet, no single treatment stands out as the most effective remedy for all men with Peyronie's disease. Further controlled, large-scale studies are necessary to establish the benefits of these nonsurgical approaches. In the meantime, combination therapy appears to make sense in the nonsurgical treatment of men with Peyronie's disease.

show abstract

“…23 Colchicine has been used both as a primary oral therapy for PD, as well as in combination with other modalities. Kadioglu et al 24 treated 60 patients in the acute phase of PD (mean duration 5.7 months ± 4.3 months), using 1 mg of colchicine twice daily, with a mean follow-up of 11 months. They found significant improvement of pain in 95% of men; however, although 30% of patients reported improved curvature, 22% of patients reported worsened curvature.…”

Section: Colchicinementioning

confidence: 99%